Clinical Trials Directory

Trials / Conditions / Alkylating Agent-Related Acute Myeloid Leukemia

Alkylating Agent-Related Acute Myeloid Leukemia

15 registered clinical trials studyying Alkylating Agent-Related Acute Myeloid Leukemia.

StatusTrialSponsorPhase
CompletedLenalidomide in Treating Patients With High Risk Acute Myeloid Leukemia in Remission
NCT02126553
M.D. Anderson Cancer CenterPhase 2
CompletedDEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or A
NCT01834248
Roswell Park Cancer InstitutePhase 1
CompletedErlotinib Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
NCT01664897
M.D. Anderson Cancer CenterPhase 2
CompletedCytarabine With or Without SCH 900776 in Treating Adult Patients With Relapsed Acute Myeloid Leukemia
NCT01870596
National Cancer Institute (NCI)Phase 2
Active Not RecruitingDecitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia
NCT01627041
National Cancer Institute (NCI)Phase 2
CompletedTipifarnib in Treating Older Patients With Acute Myeloid Leukemia
NCT01361464
National Cancer Institute (NCI)Phase 2
CompletedCaspofungin Versus Fluconazole in Preventing Invasive Fungal Infections (IFI) in Patients Undergoing Chemother
NCT01307579
Children's Oncology GroupPhase 3
TerminatedAzacitidine, Mitoxantrone Hydrochloride, and Etoposide in Treating Older Patients With Poor-Prognosis Acute My
NCT01260714
National Cancer Institute (NCI)Phase 1
CompletedLenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers
NCT01254578
National Cancer Institute (NCI)Phase 1
CompletedBusulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacit
NCT01168219
National Cancer Institute (NCI)Phase 2
CompletedVeliparib and Temozolomide in Treating Patients With Acute Leukemia
NCT01139970
National Cancer Institute (NCI)Phase 1
CompletedLenalidomide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia
NCT01132586
National Cancer Institute (NCI)Phase 1
CompletedAzacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonoc
NCT00313586
National Cancer Institute (NCI)Phase 2
CompletedSorafenib in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndromes, or Blast
NCT00217646
National Cancer Institute (NCI)Phase 1
CompletedTipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
NCT00093470
National Cancer Institute (NCI)Phase 3